186 Neb. Admin. Code, ch. 1, Attachment 1

Current through September 17, 2024
Attachment 186-1-1 - DATA ITEMS REQUIRED BY THE NEBRASKA CANCER REGISTRY FROM CANCER REPORTING SOURCES

ltem#

Item Name

70

Address at Diaqnosis-City

80

Address at Diagnosis-State

90

County at Diagnosis

100

Address at Diagnosis-Postal Code

150

Marital Status at Diagnosis

160

Race 1

161

Race 2

162

Race 3

163

Race 4

164

Race 5

170

Race Coding System-Current

180

Race Coding System-Original

190

Spanish/Hispanic Origin

220

Sex

230

Age at Diagnosis

240

Birth Date

250

Birthplace

260

Religion*

310

Text-Usual Occupation*

320

Text-Usual Industry*

340

Tobacco History*

350

Alcohol History*

360

Family History of Cancer*

390

Date of Diagnosis

400

Primary Site

410

Laterality

419

Morphology-Type & Behavior ICD- 0-2H

420

Histology ( 92-00) ICD- 0-2H

430

Behavior ( 92-00) ICD- 0-2H

440

Grade

450

Site Coding System-Current

460

Site Coding System-Original

470

Morphology Coding System-Current

480

Morphology Coding System-Original

490

Diagnostic Confirmation

500

Type of Reporting Source

521

Morphology-Type & Behavior ICD-O-3

523

Behavior Code ICD-O-3

540

Reporting Hospital

550

Accession Number-Hospital

560

Seguence Number-Hospital

570

Abstracted By

580

Date of 1st Contact

610

Class of Case

620

Year First Seen This Cancer*

630

Primary Payer at Diagnosis

670

Treatment Hospital-Surgery Primary Site

672

Treatment Hospital-Scope Regional Lymph Node Surgery

674

Treatment Hospital-Surgery Other Regional/Distant

700

Treatment Hospital-Chemotherapy

710

Treatment Hospital-Hormone Therapy

720

Treatment Hospital-lmmunotherapv

730

Treatment Hospital-Other

740

Treatment Hospital-Diagnosis/Staging Procedure

759

SEER Summary Stage 2000

760

SEER Summary Stage 1977H

780

Extent of disease-Tumor Size

820

Regional Nodes Positive

830

Regional Nodes Examined

880

TNM Pathologic Tumor

890

TNM Pathologic Nodes

900

TNM Pathologic Metastases

910

TNM Pathologic Stage Group

920

TNM Pathologic Descriptor

930

TNM Pathologic Staged By

940

TNM Clinical Tumor

950

TNM Clinical Nodes

960

TNM Clinical Metastases

970

TNM Clinical Stage Group

980

TNM Clinical Descriptor

990

TNM Clinical Staged By

1060

TNM Edition Number

1150

Tumor Marker 1*

1160

Tumor Marker 2*

1170

Tumor Marker 3*

1200

Treatment Date-Surgery

1210

Treatment Date-Radiation

1250

Treatment Date-Other

1270

Date of 1st Course of Treatment-COC

1280

Treatment Date-Diagnosis/Staging Procedure

1290

Treatment Summary-Surgery Primary Site

1292

Treatment Summary-Scope Regional Lymph Nodes Surgery

1294

Treatment Summary-Surgery Other Regional/Distant

1320

Treatment Summary-Surgical Margins

1340

Reason for No Surgery

1350

Treatment Summarv-Diagnosis/Staging Procedure

1380

Treatment Summarv-Surgerv/Radiation Seguence

1390

Treatment Summary-Chemotherapy

1400

Treatment Summary-Hormone Therapy

1410

Treatment Summarv-lmmunotherapv

1420

Treatment Summary-Other

1430

Reason for No Radiation Therapy

1460

Treatment Coding System-Current

1510

Radiation-Regional Dose: cGy

1520

Radiation-Number of Treatment Volume

1540

Radiation-Treatment Volume

1550

Radiation-Location of Treatment

1570

Radiation-Regional Treatment Modality

1660

Subseguent Treatment 2nd Course Date*

1670

Subseguent Treatment 2nd Course Codes*

1671

Subseguent Treatment 2nd Course Surgery*

1672

Subseguent Treatment 2nd Course Radiation*

1673

Subseguent Treatment 2nd Course Chemotherapy*

1674

Subseguent Treatment 2nd Course Hormone Therapy*

1675

Subseguent Treatment 2nd Course Immunotherapy*

1676

Subseguent Treatment 2nd Course Other*

1677

Subseguent Treatment 2nd-Scope Lymph Nodes Surgery*

1678

Subseguent Treatment 2nd-Surgery Other*

1679

Subseguent Treatment 2nd-Regional Lymph Nodes Removed*

1680

Subsequent Treatment 3rd Course Date*

1690

Subsequent Treatment 3rd Course Codes*

1691

Subsequent Treatment 3rd Course Surqery*

1692

Subsequent Treatment 3rd Course Radiation*

1693

Subsequent Treatment 3rd Course Chemotherapy*

1694

Subsequent Treatment 3rd Course Hormone Therapy*

1695

Subsequent Treatment 3rd Course Immunotherapy*

1696

Subsequent Treatment 3rd Course Other*

1697

Subsequent Treatment 3rd-Scope Lymph Nodes Surqery*

1698

Subsequent Treatment 3rd-Surqerv Other*

1699

Subsequent Treatment 3rd-Reqional Lymph Nodes Removed*

1700

Subsequent Treatment 4th Course Date*

1710

Subsequent Treatment 4th Course Codes*

1711

Subsequent Treatment 4th Course Surqery*

1712

Subsequent Treatment 4th Course Radiation*

1713

Subsequent Treatment 4th Course Chemotherapy*

1714

Subsequent Treatment 4th Course Hormone Therapy*

1715

Subsequent Treatment 4th Course Immunotherapy*

1716

Subsequent Treatment 4th Course Other*

1717

Subsequent Treatment 4th-Scope Lymph Nodes Surqery*

1718

Subsequent Treatment 4th-Surqerv Other*

1719

Subsequent Treatment 4th-Reqional Lymph Nodes Removed

1720

Subsequent Treatment 5th Course Date

1730

Subsequent Treatment 5th Course Codes

1731

Subsequent Treatment 5th Course Surqery*

1732

Subsequent Treatment 5th Course Radiation*

1733

Subsequent Treatment 5th Course Chemotherapy*

1734

Subsequent Treatment 5th Course Hormone Therapy*

1735

Subsequent Treatment 5th Course Immunotherapy*

1736

Subsequent Treatment 5th Course Other*

1737

Subsequent Treatment 5th-Scope Lymph Nodes Surqery*

1738

Subsequent Treatment 5th-Surqerv Other*

1739

Subsequent Treatment 5th-Reqional Lymph Nodes Removed*

1750

Date of Last Contact

1760

Vital Status

1770

Cancer Status

1790

Follow-Up Source

1800

Next Follow-Up Source

1810

Address Current-City

1820

Address Current-State

1830

Address Current-Postal Code

1860

Recurrence Date-1st

1880

Recurrence Type-1st

1930

Autopsy*

1940

Place of Death*

1980

ICD-O-2 Conversion Flaq

1985

Over-ride Accession/Class of Case/Sequence

1986

Over-ride Hospital Sequence/Diaqnostic Confirmation

1987

Over-ride COC-Site/Type

1988

Over-ride Hospital Sequence/Site

1989

Over-ride Site/TNM-Staqinq Group

1990

Over-ride Aqe/Site/Morpholoqy

2020

Over-ride Surqery/Diaqnostic Confirmation

2030

Over-ride Site/Type

2040

Over-ride Histoloqy

2070

Over-ride Leukemia Lymphoma

2071

Over-ride Site/Behavior

2074

Over-ride Site/Laterality/Morphology

2110

Date Case Report Exported

2111

Date Case Report Received

2112

Date Case Report Loaded

2113

Date Tumor Record Available

2116

ICD-O-3 Conversion Flaq

2140

COC Coding System-Current

2150

COC Coding System-Original

2170

Vendor Name

2230

Name-Last

2240

Name-First

2250

Name-Middle

2270

Name-Suffix

2280

Name-Alias

2290

Name-Spouse/Parent*

2300

Medical Record Number

2310

Military Record No Suffix

2320

Social Security Number

2330

Address at Diagnosis-Number & Street

2335

Address at Diagnosis-Supplemental

2350

Address Current-Number & Street

2355

Address Current-Supplemental

2360

Telephone

2390

Name-Maiden*

2410

Institution Referred From

2420

Institution Referred To

2440

Following Registry

2460

Physician-Managing

2470

Phvsician-Follow-Up

2480

Physician-Primary Surgery

2490

Physician 3

2500

Physician 4

2520

Text-Diagnosis Procedure-Physical Exam

2530

Text-Diagnosis Procedure-X-ray/scan

2540

Text-Diagnosis Procedure-Scopes

2550

Text-Diagnosis Procedure-Lab Tests

2560

Text-Diagnosis Procedure-Operative

2570

Text-Diagnosis Procedure-Pathology

2580

Text-Primary Site Title

2590

Text-Histology Title

2600

Text-Staging

2610

Treatment Text-Surgery

2620

Treatment Text-Radiation (Beam)

2630

Treatment Text-Radiation Other

2640

Treatment Text-Chemotherapy

2650

Treatment Text-Hormone Therapy

2660

Treatment Text-lmmunotherapv

2670

Treatment Text-Other

2680

Text-Remarks

2690

Place of Diagnosis

2800

Collaborative Stage Tumor Size*

2810

Collaborative Stage Extension*

2820

Collaborative Stage Tumor Size/Extension Evaluation*

2830

Collaborative Stage Lymph Nodes*

2840

Collaborative Stage Regional Lymph Nodes Evaluation*

2850

Collaborative Stage Metastasis at Diagnosis*

2880

Collaborative Stage Site-Specific Factor 1*

2890

Collaborative Staqe Site-Specific Factor 2*

2900

Collaborative Stage Site-Specific Factor 3*

2910

Collaborative Staqe Site-Specific Factor 4*

2920

Collaborative Staqe Site-Specific Factor 5*

2930

Collaborative Staqe Site-Specific Factor 6*

2940

Derived AJCC Tumor*

2950

Derived AJCC Tumor Descriptor*

2960

Derived AJCC Lymph Nodes*

2970

Derived AJCC Lymph Nodes Descriptor*

2980

Derived AJCC Metastasis*

2990

Derived AJCC Metastasis Descriptor*

3000

Derived AJCC Staqe Group*

3010

Derived Summary Staqe (SEER)1977*

3020

Derived Summary Staqe 2000*

3030

Derived AJCC-Conversion Flaq*

3040

Derived Summary Staqe 1977-Conversion Flaq*

3050

Derived Summary Staqe 2000-Conversion Flaq

3100

Archive Federal Identification Number

3110

Comorbidities/Complication 1

3120

Comorbidities/Complication 2

3130

Comorbidities/Complication 3

3140

Comorbidities/Complication 4

3150

Comorbidities/Complication 5

3160

Comorbidities/Complication 6

3170

Treatment Date-Most Definitive Surqerv

3180

Treatment Date-Surqical Discharqe

3190

Readmission Same Hospital within 30 Days

3200

Radiation-Boost Treatment Modality

3210

Radiation-Boost Dose cGy

3220

Treatment Date-Radiation Ended

3230

Treatment Date-Systemic

3250

Treatment Summarv-Transplant/Endocrine Procedures

3270

Treatment Summary-Palliative Procedure

3280

Treatment Hospital-Palliative Procedure

Codes for Recommendations: *- Required when available. H - Historically collected and currently transmitted.

186 Neb. Admin. Code, ch. 1, Attachment 1

Amended effective 9/15/2020